NASDAQ:AGEN - Agenus Stock Price, Forecast & News

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

Agenus Inc (NASDAQ:AGEN) posted its quarterly earnings data on Monday, November, 4th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.38) by $0.05. The biotechnology company had revenue of $19.94 million for the quarter, compared to the consensus estimate of $15.60 million. View Agenus' Earnings History.

Agenus is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Agenus.

1 equities research analysts have issued twelve-month price targets for Agenus' stock. Their forecasts range from $6.00 to $6.00. On average, they anticipate Agenus' share price to reach $6.00 in the next twelve months. This suggests a possible upside of 56.7% from the stock's current price. View Analyst Price Targets for Agenus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agenus.

News coverage about AGEN stock has been trending somewhat positive recently, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Agenus earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Agenus.

Some companies that are related to Agenus include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Agenus investors own include Rosetta Genomics (ROSG), Exelixis (EXEL), Merrimack Pharmaceuticals (MACK), REDHILL BIOPHAR/S (RDHL), Opko Health (OPK), Gilead Sciences (gild), Energy Transfer LP Unit (ET), Synergy Pharmaceuticals (SGYP), Novavax (NVAX) and Cara Therapeutics (CARA).

Agenus' stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (1.75%), Millennium Management LLC (0.55%), Alps Advisors Inc. (0.20%), California Public Employees Retirement System (0.13%), California State Teachers Retirement System (0.12%) and Barclays PLC (0.05%). View Institutional Ownership Trends for Agenus.

AGEN stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Barclays PLC, Alberta Investment Management Corp, Metropolitan Life Insurance Co NY and Alps Advisors Inc.. View Insider Buying and Selling for Agenus.

AGEN stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Millennium Management LLC, California Public Employees Retirement System, Commonwealth Equity Services LLC, Virtu Financial LLC and California State Teachers Retirement System. View Insider Buying and Selling for Agenus.

Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AGEN stock can currently be purchased for approximately $3.83.

Agenus has a market capitalization of $526.09 million and generates $36.78 million in revenue each year. The biotechnology company earns $-159,690,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. Agenus employs 294 workers across the globe.View Additional Information About Agenus.

The official website for Agenus is http://agenusbio.com/.

Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-674-4400 or via email at [email protected]